Dr. DiNardo is an academic clinical researcher directing multiple clinical trials within myeloid malignancies, especially early Phase 1 and Phase 2 clinical trials.  She is helping to spear-head the clinical development of a new class of targeted therapies; namely the targeted IDH1 and IDH2 inhibitors for patients with myeloid malignancies, as well as combination strategies including the oral BCL2 inhibitor venetoclax.  She has pioneered the utility of obtaining 2HG measurements in patients with AML and MDS, and the potential role for utilizing 2HG measurements to identify patients with IDH1 and/or IDH2 mutations.  Dr. DiNardo is now leading the accrual of multiple sponsored combination IDH-targeted treatment strategies, and is running several investigator-initiated Phase II combination trials with IDH and BCL2 inhibitors. 

Dr. DiNardo’s career goal is to provide a comprehensive and personalized cancer risk assessment for every leukemia patient based upon a detailed understanding of the genomic aberrations contributing to their development of malignancy, leading to a successful and individualized therapeutic approach.  Targeted treatment paradigms, including the development of preventative techniques for patients at risk of hematologic malignancy and innovative clinical trial designs for molecularly-defined subgroups, are the focus of her clinical research.